Thermo Fisher Scientificの空売り状況は、投資家がThermo Fisher Scientificの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

Thermo Fisher Scientific (NYSE:TMO) 株価情報, 空売り情報

THERMO FISHER SCIENTIFIC INC

Thermo Fisher Scientific

Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents. The firm operates through four segments as of year end-2024 (revenue figures include some cross-segment revenue): analytical technologies (17% of sales); specialty diagnostic products (11%); life science solutions (23%); and lab products and services, which includes CRO services (54%).

Thermo Fisher Scientific Inc Common Stock

Thermo Fisher Scientific Inc

TomTom NV

TOMOE ENGINEERING CO by Tomoe Engineering Co. Ltd.

Tomoe Engineering Co Ltd

Trimol Group Inc

Thermo Fisher Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>) has outperformed the market over the past 20 years by 6.51% on an annualized basis producing an average annual return of 14.67%. Currently, Thermo Fisher Scientific has a market capitalization of $155.19 billion. 
Buying $100 In TMO: If an investor had bought $100 of TMO stock 20 years ago, it would be worth $1,584.63 today based on a price of $411.37 for TMO at the time of writing.
<h3>Thermo Fisher Scientific's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1746716419_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

News

Trading Ideas

Here's How Much You Would Have Made Owning Thermo Fisher Scientific Stock In The Last 20 Years

The U.S. Food and Drug Administration (FDA) announced its intent to expand the use of unannounced inspections at foreign manufacturing facilities that produce foods, essential medicines, and other medical products intended for <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">American consumers and patients</a>.
This change builds upon the agency&#8217;s Office of Inspection and Investigations&#8217; Foreign Unannounced Inspection Pilot program in India and China and aims to ensure that foreign companies will receive the same level of regulatory oversight and scrutiny as domestic companies.&nbsp;
&#8220;For too long, foreign companies have enjoyed a double standard—given advanced notice before facility inspections, while American manufacturers are held to rigorous standards with no such warning,&#8221; said FDA Commissioner Martin Makary. &nbsp;
On Tuesday, the FDA <a target="_blank" href="https://www.fda.gov/news-events/press-announcements/fda-announces-expanded-use-unannounced-inspections-foreign-manufacturing-facilities?utm_medium=email&amp;utm_source=govdelivery" rel="noreferrer noopener">said</a> it plans to review and improve its foreign inspection program to ensure it meets the highest standards for oversight. Part of this effort includes making it clear that FDA inspectors should not accept travel-related perks like hotel stays or transportation from the companies they inspect.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/health-care/25/05/45225204/iqvia-beats-q1-earnings-expectations-despite-sector-uncertainty-company-navigating-market-conditions-effectively-says-ceo" rel="noreferrer noopener">IQVIA Beats Q1 Earnings Expectations Despite Sector Uncertainty, Company Navigating Market Conditions &#8216;Effectively&#8217; Says CEO</a>
The FDA conducts about 12,000 inspections annually in the U.S. and 3,000 in other countries. While U.S. companies often get surprise inspections, foreign companies usually receive advanced notice, giving them time to prepare and potentially hide problems.
Still, foreign inspections often reveal serious issues, more than twice as often as domestic ones.
In the U.S., inspections are usually unannounced unless specific programs require advance notice to ensure staff and records are available.
Even then, companies can&#8217;t pick the date or time. The FDA says foreign companies shouldn&#8217;t have that option either.
By shifting to more surprise inspections abroad, the FDA aims to better protect American consumers by catching dishonest practices, like falsifying records or hiding violations, before they cause harm.
The agency can take action against any company that tries to delay, block, or refuse an unannounced inspection.
The update follows President&nbsp;Donald Trump&#8217;s signed executive order on Monday to promote prescription drug manufacturing in the U.S., streamlining the path for companies to build new production sites as potential tariffs on <a target="_blank" href="https://www.benzinga.com/topic/tariffs" rel="noreferrer noopener">imported medicines loom</a>.
The order directs the FDA to reduce the amount of time it takes to approve manufacturing plants in the U.S. by eliminating unnecessary requirements, streamlining reviews, and working with domestic drugmakers to &#8220;provide early support before facilities come online,&#8221; <a target="_blank" href="https://www.whitehouse.gov/fact-sheets/2025/05/fact-sheet-president-donald-j-trump-announces-actions-to-reduce-regulatory-barriers-to-domestic-pharmaceutical-manufacturing/" rel="noreferrer noopener">according</a> to&nbsp;a White House fact sheet.
It also directs the agency to raise inspection fees for foreign manufacturing plants, improve the enforcement of active-ingredient source reporting by overseas producers, and consider publicly listing facilities that don&#8217;t comply.
The White House <a target="_blank" href="https://www.whitehouse.gov/presidential-actions/2025/05/regulatory-relief-to-promote-domestic-production-of-critical-medicines/" rel="noreferrer noopener">estimates</a> that it can currently take five to ten years to build new pharmaceutical manufacturing capacity, which it calls &#8220;unacceptable from a national-security standpoint.&#8221;
<a target="_blank" href="https://www.benzinga.com/markets/25/02/43906811/trump-reportedly-warns-big-pharma-move-manufacturing-to-us-or-face-tariffs" rel="noreferrer noopener">Amid tariff uncertainty</a>, many companies have disclosed a wave of investments in recent months to boost production in the U.S.
<ul>
<li>Eli Lilly And Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) doubled <a href="https://www.benzinga.com/general/biotech/25/02/43982604/eli-lilly-doubles-capital-spending-on-us-drug-manufacturing-with-50-billion-target" target="_blank" rel="noreferrer noopener">domestic medicine production</a>.</li>
<li>Thermo Fisher Scientific Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>) announced it would invest an additional $2 billion in the U.S. over <a href="https://www.benzinga.com/general/health-care/25/04/44995428/thermo-fisher-doubles-down-on-us-manufacturing-in-2b-expansion-plan" target="_blank" rel="noreferrer noopener">the next four years</a>.</li>
<li>Medtech firm Becton, Dickinson, and Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BDX#NYSE">BDX</a>) also announced its intention to invest $2.5 billion in U.S. manufacturing capacity <a href="https://www.benzinga.com/general/health-care/25/05/45140102/potential-tariff-bites-into-becton-dickinson-2025-profit-outlook-company-will-invest-2-5-billion-to-boost-us-manufacturing" target="_blank" rel="noreferrer noopener">over the next 5 years</a>.</li>
<li>Pfizer Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) did not highlight investments in new manufacturing plants; it noted that they already have significant capacity and flexibility to manufacture <a href="https://www.benzinga.com/general/biotech/25/04/45118145/pfizer-ceo-albert-bourla-emphasizes-national-security-in-us-drug-manufacturing" target="_blank" rel="noreferrer noopener">their products in the U.S</a>.</li>
<li>Regeneron Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) seeks to nearly double its manufacturing capacity through a new agreement with <a href="https://www.benzinga.com/general/biotech/25/04/44931246/regeneron-partners-with-japan-based-fujifilm-to-bolster-us-manufacturing-capacity-via-3-billion-deal" target="_blank" rel="noreferrer noopener">FUJIFILM Diosynth Biotechnologies</a>.</li>
<li>Novartis AG (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVS#NYSE">NVS</a>) unveiled a sweeping $23 billion investment plan to expand its manufacturing and research infrastructure in the U.S. <a href="https://www.benzinga.com/general/biotech/25/04/44761201/novartis-commits-23-billion-to-expand-us-manufacturing-over-five-years-despite-tariffs-uncertaint" target="_blank" rel="noreferrer noopener">over the next five years</a>.</li>
<li>Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) announced its plans to invest more than <a href="https://www.benzinga.com/markets/equities/25/03/44433978/johnson-johnson-to-invest-55-billion-in-us-to-boost-manufacturing-drug-discovery" target="_blank" rel="noreferrer noopener">$55 billion in the U.S. over the next four years</a>.</li>
<li>Roche Holdings AG (OTC:<a class="ticker" href="https://www.benzinga.com/stock/RHHBY#OTC">RHHBY</a>) announced that it will invest $50 billion in the U.S. over <a href="https://www.benzinga.com/topic/pharmaceuticals" target="_blank" rel="noreferrer noopener">the next five years.</a></li>
<li>Most recently, Bristol-Myers Squibb &amp; Co.&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) Christopher Boerner, chair and chief executive officer, <a href="https://www.statnews.com/2025/05/05/bristol-myers-squibb-pharmaceutical-policy-us-trump-administration-innovation-tariffs/" target="_blank" rel="noreferrer noopener">shared</a> plans to invest $40 billion in U.S. R&amp;D, technology, and manufacturing over the next five years in an op-ed published by Stat this week.</li>
</ul>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/25/05/45195137/footwear-titans-nike-adidas-call-tariffs-an-existential-threat-appeal-to-trump-for-relief-this-is-an-emergency" target="_blank" rel="noreferrer noopener">Footwear Titans Nike, Adidas Call Tariffs An &#8216;Existential Threat&#8217;, Appeal To Trump For Relief: &#8216;This Is An Emergency&#8217;</a></li>
</ul>
Photo by Tada Images via Shutterstock

Biotech

Government

Large Cap

Regulations

Health Care

General

REGN

RHHBY

FDA Expands Surprise Inspections At Foreign Drug And Food Facilities, Targets Double Standards In Overseas Manufacturing Oversight

As May opens for business, shell-shocked stock market investors are waving goodbye to April with both hands. While the major stock indexes have <a href="https://www.benzinga.com/markets/25/04/45027002/benzinga-bulls-and-bears-netflix-novavax-intel-and-the-market-begins-to-bounce-back">bounced back</a> moderately over the last week, stocks fell 11% at one point and declined 20% since mid-February, primarily due to <a href="https://www.benzinga.com/trading-ideas/25/04/45050322/how-youll-know-the-tariff-troubles-are-over">tariff troubles</a> affecting the global economy.
That's not all. Consumer spending was at a two-year low in the first quarter of 2025, while first-quarter US gross domestic product fell by 0.3%, fueling talk of a recession on the horizon.
Older traders are talking about a &#8220;Templeton Moment&#8221; right now, and likely with good reason. The term stems from legendary trader John Templeton, who famously borrowed $10,000 to buy shares in every company trading on the New York Stock Exchange for under $1 during a market trough in 1939, during the Great Depression. The list included 104 companies, including 34 that were bankrupt. A few years later, Templeton banked huge gains on all but four stocks when he sold.
Today&#8217;s market could be your opportunity for something similar.
"It doesn&#8217;t resemble a &#8216;Templeton Moment,&#8217; but I would be cautious," said Eugenia Mykuliak, founder and executive director at B2PRIME Group, a global financial services provider for institutional investors. "Today&#8217;s market has more nuances, and we're not close to an &#8216;extreme&#8217; pessimism, unlike the 1930s. Even though there are some well-valued stocks out there, that's certainly not an invitation to buy in bulk."
Unlike the 1930's, which saw economic indicators drag across the board, this market has largely fallen victim to one malady.
&#8220;Uncertainty has been generated by the announcement, delay, magnitude, and duration of tariffs," said Karl Farmer, portfolio manager at Rockland Trust Bank. "With over 40% of the S&amp;P 500's revenues coming from outside the US, the tariffs can have some big impacts on inventory management and purchase plans as producers and consumers face higher prices."
Resulting market uncertainty means less confidence in profit consistency and usually lower multiples that investors place on earnings.
"Higher costs likely lead to lower profits if sellers cannot pass on the price increases to their customers, or at a minimum, it leads to lower consumption," Farmer said. "A lower multiple coupled with lower profits means lower market levels. The longer the tariffs remain, the more likely there will be behavior changes by both producers and consumers, as many will seek alternatives if they believe that higher prices are not temporary."
If the delayed reciprocal tariffs are implemented in full and there have been few negotiated breakthroughs, "then we have not seen the bottom," Farmer added.
Here are today&#8217;s buying opportunities and what to look out for.
<h2 class="wp-block-heading">Stocks To Pounce On At Lower Market Levels</h2>
Templeton or no Templeton, when the markets slide significantly, there's always low-hanging fruit available, and the US stock market is no different. Here are a few names that stock market gurus like in a shallower pricing market.
British American Tobacco (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BTI#NYSE">BTI</a>). Sluggish stock markets spell opportunity for stocks that demonstrate good resilience amid uncertainty, especially those that turn to future-oriented technologies, Mykuliak said.
Shopify (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHOP#NASDAQ">SHOP</a>). Mykuliak also likes stocks that offer investors a double dose of value.
"Shopify could be another good example of a perfect combination of AI and e-commerce, which are two powerful trends today," she said. "If merchants want to adapt to new retail realities, it&#8217;s a top choice for them."
Nike (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NKE#NYSE">NKE</a>). According to Farmer, defensive sectors such as consumer staples and utilities have held up very well this year. "Presently, we favor some names in other areas that may have been overly punished, but could provide above-average returns for the patient investor," he said.
Nike tops that list. Nike is no quick fix for a 2025 portfolio, but it makes sense in this market.
"A pop could be had here if tariffs end quickly," Farmer said. "Nike did have issues even before tariffs, but it's a reinvigorating brand, and it's repairing relationships. Plus, Nike shares are down 70% from peak to 2017 levels, which provides a decent entry point."
Air Products and Chemicals (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APD#NYSE">APD</a>). Air Products is a market leader in industrial gas trading at a big discount to competitor Linde (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIN#NASDAQ">LIN</a>). "Future growth is coming from new projects and clean energy transition," Farmer said. "Additionally, the company has a strong and predictable recurring revenue model with on-site plants and 20-year contracts." Thermo Fisher Scientific (NYSE: TMO) is a market leader in life sciences, diagnostics and instruments.
"The stock is off 30% in the last three months on fears of spending cutbacks from customers who rely on federal funding for research," Farmer notes. "It's trading at less than market multiples for better earnings growth. Meanwhile, clarity on federal funding should mark a bottom."
<h2 class="wp-block-heading">More Than A "Buy the Dip" Scenario</h2>
As uncertainty prevails in the stock market, money managers are taking a more defensive stance with their portfolios, with one eye on historical trends.
"Historically, when volatility spikes—as it did in early April—the equity markets tend to see large gains one year later," said Andrew Constantinides, a financial advisor at Neil Jesani Wealth Management. "In the short term, however, calling the bottom is much harder. Investors should always remember: There can always be more downside in the market—unless it's at zero."
Constantinides said his firm is primarily focused on value and international stocks.
"Both categories have underperformed U.S. growth stocks over the past 10 years," he noted. "But Q1 of 2025 showed the first real signs of a cycle shift back toward value and international leadership. We favor developed markets, such as Europe and Asia. Our current sector focus is energy and financials—companies with low price-to-earnings ratios and high earnings yield. We have almost no exposure to large-cap tech."
<h2 class="wp-block-heading">5 Dark Horse Stocks Most Investors Aren't Following (But Should)</h2>
Every Friday, five overlooked stocks land on our ‘Whisper Index.' Like Coinbase before it surged 245% higher. And the biotech breakthrough Insmed before it jumped 20% in a single month. Beat Wall Street to these next potential winners. Access the Whisper Index <a href="https://www.benzinga.com/premium/ideas/benzinga-edge/?el=ResearchDaily&amp;he={{email}}&amp;adt_ei={{email}}&amp;utm_adType=SponsorAd&amp;utm_ad=RD0505&amp;utm_campaign=commandcenter">HERE</a>.
Editorial content from our Expert contributors is intended to be information for the general public and not individualized investment advice. Editors/contributors are presenting their individual opinions and strategies, which are neither expressly nor impliedly approved or endorsed by Benzinga.
Photo: Shutterstock

Opinion

SHOP

This Market Is The Buying Opportunity Of A Lifetime

Argus Research analyst David Toung maintains Thermo Fisher Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>) with a Buy and lowers the price target from $620 to $470.

Price Target

Analyst Ratings

Argus Research Maintains Buy on Thermo Fisher Scientific, Lowers Price Target to $470

Thermo Fisher Scientific's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>) short percent of float has risen 20.95% since its last report. The company recently reported that it has 4.79 million shares sold short, which is 1.27% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.52 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Thermo Fisher Scientific Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1745866842_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Thermo Fisher Scientific has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Thermo Fisher Scientific's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Thermo Fisher Scientific's peer group average for short interest as a percentage of float is 7.35%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Is Thermo Fisher Scientific Gaining or Losing Market Support?

With earnings season in full swing, let&#8217;s examine the performance of some major healthcare, utility, and financial services companies in Dan Loeb&#8216;s Third Point LLC portfolio that <a href="https://www.benzinga.com/earnings" target="_blank" rel="noreferrer noopener">reported earnings last week</a>.
Thermo Fisher Scientific Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>): Loeb acquired a stake in the company, attaining 350,000 shares <a target="_blank" href="https://www.benzinga.com/news/large-cap/25/02/43945075/dan-loeb-adjusts-healthcare-holdings-danaher-stake-trimmed-as-thermo-fisher-gains-favor" rel="noreferrer noopener">in the fourth quarter 2024</a>.
<ul>
<li>On April 23, the company reported&nbsp;first-quarter&nbsp;2025 adjusted earnings per share of&nbsp;$5.15,&nbsp;<a href="https://www.benzinga.com/calendars/earnings" target="_blank" rel="noreferrer noopener">beating the street view of&nbsp;$5.10</a>.</li>
<li>Quarterly sales of&nbsp;$10.36 billion, almost flat year over year, outpaced the analyst <a href="https://www.benzinga.com//node/44956678" target="_blank" rel="noreferrer noopener">consensus estimate of&nbsp;$10.23 billion</a>.</li>
<li>Thermo Fisher Scientific lowered 2025 adjusted EPS&nbsp;outlook from&nbsp;$23.10-$23.50&nbsp;to&nbsp;$21.76-$22.84&nbsp;vs. the consensus of&nbsp;$23.25 and revised sales&nbsp;guidance&nbsp;from&nbsp;$43.5 billion-$44 billion&nbsp;to&nbsp;$43.3 billion-$44.2 billion&nbsp;vs. consensus of&nbsp;$43.84 billion.</li>
<li>The company expects U.S.-China tariffs to hurt sales in China for products made in the U.S. This will reduce revenue by&nbsp;$400 million&nbsp;in 2025. These tariffs will also raise the cost of parts and <a href="https://www.benzinga.com//node/44966173" target="_blank" rel="noreferrer noopener">subassemblies sourced from China</a>.</li>
<li>After accounting for lower sales and higher costs—despite efforts to reduce the impact—the company expects adjusted operating income to take a&nbsp;$375 million&nbsp;hit compared to previous&nbsp;guidance.</li>
<li>Several analysts lowered the price <a href="https://www.benzinga.com/quote/TMO/analyst-ratings" target="_blank" rel="noreferrer noopener">forecast following the results</a>.</li>
<li>On April 24, the company said&nbsp;that it would invest an additional&nbsp;$2 billion&nbsp;in the <a href="https://www.benzinga.com//node/44995428" target="_blank" rel="noreferrer noopener">U.S. over&nbsp;the next four years</a>.</li>
<li>Year to date, Thermo Fisher fell about 21.03%, both underperforming the&nbsp;iShares U.S. Healthcare ETF&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IYH#NYSE">IYH</a>), which declined about 2.36%&nbsp;over the same time frame.</li>
</ul>
Pacific Gas &amp; Electric Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PCG#NYSE">PCG</a>): The investor had cut the stake from 49.75 million shares in the&nbsp;third quarter&nbsp;of 2024 to 48.5 million in <a target="_blank" href="https://www.benzinga.com//node/44384767" rel="noreferrer noopener">the&nbsp;fourth quarter&nbsp;of 2024</a>.
<ul>
<li>On April 24, the company reported first-quarter adjusted EPS of 33&nbsp;cents, down from 37 cents in the prior-year quarter and missing the estimates of 35 cents. Sales&nbsp;of $5.98 billion came below the <a href="https://www.benzinga.com/pressreleases/25/04/n44973765/pg-e-corporation-reports-first-quarter-results-on-track-to-deliver-solid-2025-residential-electric" target="_blank" rel="noreferrer noopener">street view of&nbsp;$6.13 billion</a>.</li>
<li>The company reiterated 2025 guidance for adjusted EPS at $1.48-$1.52&nbsp;compared to consensus of $1.50.</li>
<li>The company showed confidence in its equity strength, which is &#8216;fully satisfied&#8217; to fund the five-year capital plan of&nbsp;$63 billion&nbsp;through 2028.</li>
<li>Guggenheim analyst Shahriar Pourreza maintained a Neutral and raised the price forecast from&nbsp;$16&nbsp;to&nbsp;$17. Evercore ISI Group analyst Michael Lonegan retained an In-Line rating and boosted the <a href="https://www.benzinga.com/quote/pcg/analyst-ratings" target="_blank" rel="noreferrer noopener">price forecast from&nbsp;$15&nbsp;to&nbsp;$17</a>.</li>
<li>The company&#8217;s shares dipped around&nbsp;15.88%&nbsp;so far in 2025 compared to&nbsp;VanEck Uranium and Nuclear ETF&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NLR#NYSE">NLR</a>) decline of 11.27%.</li>
</ul>
Discover Financial Services (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DFS#NYSE">DFS</a>): Loeb had acquired 640,000 shares in the company<a target="_blank" href="https://www.benzinga.com/25/04/44698171/trumps-tariff-push-sends-financials-lower-loebs-portfolio-take-a-hit" rel="noreferrer noopener"> in the fourth quarter of 2024</a>.
<ul>
<li>On April 23, the company reported first-quarter EPS of&nbsp;$4.25, which beat the analyst consensus estimate of&nbsp;$3.39&nbsp;by&nbsp;25.37%. Revenue of $4.25 billion, exceeded the analyst<a href="https://www.benzinga.com//node/44967199" target="_blank" rel="noreferrer noopener"> consensus estimate of&nbsp;$4.22 billion</a>.</li>
<li>Provision for credit losses of&nbsp;$1.2 billion&nbsp;decreased&nbsp;$253 million&nbsp;from the prior year quarter, driven by a&nbsp;$190 million&nbsp;favorable reserve change and a&nbsp;$97 million&nbsp;decrease in net charge-offs.</li>
<li>The company confirmed that it expects the merger with&nbsp;Capital One Financial Corp.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COF#NYSE">COF</a>) to close on or about May 18, 2025.</li>
<li>TD Securities analyst Moshe Orenbuch maintained a Buy rating and slashed the price forecast from&nbsp;$188&nbsp;to&nbsp;$184, while Truist Securities analyst Brian Foran boosted the <a href="https://www.benzinga.com/quote/dfs/analyst-ratings" target="_blank" rel="noreferrer noopener">price forecast from&nbsp;$219&nbsp;to&nbsp;$229</a>.</li>
<li>The stock rose 4.98% compared to iShares Focused Value Factor ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FOVL#NYSE">FOVL</a>) decline of 5.67% YTD.</li>
</ul>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/tech/25/04/44911125/dan-loebs-bet-on-taiwan-semiconductor-looks-strong-as-q1-results-top-expectations" target="_blank" rel="noreferrer noopener">Dan Loeb&#8217;s Bet On Taiwan Semiconductor Looks Strong As Q1 Results Top Expectations</a></li>
</ul>
Image: Shutterstock

Equities

FOVL

iShares Trust Dow Jones US Healthcare Sector Index Fund

Tariffs Bite Dan Loeb's Portfolio: Thermo Fisher Hit Hard, Discover Shines

Scotiabank analyst Sung Ji Nam maintains Thermo Fisher Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>) with a Sector Perform and lowers the price target from $650 to $605.

Scotiabank Maintains Sector Perform on Thermo Fisher Scientific, Lowers Price Target to $605

Thermo Fisher Scientific Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>) announced Thursday that it would invest an additional $2 billion in the U.S. over <a href="https://www.benzinga.com/general/health-care" target="_blank" rel="noreferrer noopener">the next four years</a>.
As one of the largest manufacturers of medicines in the world, Thermo Fisher enables biopharma companies to develop and produce their <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/b44976531/thermo-fisher-scientific-invests-to-enhance-u-s-innovation-and-support-customers-manufacturing" rel="noreferrer noopener">medicines in America</a>.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/health-care/25/04/44966205/analyst-sees-opportunity-in-danaher-stock-as-sentiment-improves" rel="noreferrer noopener">Analyst Sees Opportunity In Danaher Stock As Sentiment Improves</a>
These additional investments to the company&#8217;s American manufacturing capacity support a resilient U.S. healthcare supply chain and will have a strong multiplier effect across the American economy.
The $2 billion investment over the next four years includes:
<ul>
<li>$1.5 billion in capital expenditures to enhance and expand U.S. manufacturing operations</li>
<li>Complemented by $500 million in R&amp;D focused on high-impact innovation</li>
</ul>
Thermo Fisher CEO Marc N. Casper explained that by expanding in the U.S., the company ensures that &#8220;life-saving medicines and therapies will continue to be developed and produced in America for decades to come.&#8221;
This investment builds on Thermo Fisher&#8217;s 64 U.S. manufacturing operations in 37 states.
The company also invests $1 billion annually in R&amp;D in the U.S.
Over the next four years, the company will continue to expand its impact in the U.S. by creating high-paying jobs, adding manufacturing and lab services capacity, and investing in research and development.
On Wednesday, Thermo Fisher said that it expects U.S.-China tariffs to hurt sales in China for products made in the U.S. The company estimates this will reduce revenue by $400 million in 2025. These tariffs will also raise the cost of parts and subassemblies <a target="_blank" href="https://www.benzinga.com/general/health-care/25/04/44966173/thermo-fisher-beats-q1-estimates-lowers-full-year-forecast-as-tariffs-and-costs-take-a-toll" rel="noreferrer noopener">sourced from China</a>.
After accounting for lower sales and higher costs—despite efforts to reduce the impact—the company expects adjusted operating income to take a $375 million hit compared to previous guidance.
Analyst Reactions on Thursday:
<ul>
<li>Baird maintains Thermo Fisher Scientific with an Outperform, lowering the price target from $603 to $573.</li>
<li>Wells Fargo maintains Thermo Fisher with an Overweight rating and lowers the price target from $580 to $570.</li>
<li>Evercore ISI maintains Thermo Fisher with an Outperform, lowering the price target from $585 to $500.</li>
<li>Stifel reaffirms the Buy rating for Thermo Fisher, lowering the price target from $665 to $620.</li>
</ul>
Price Action: TMO stock is down 2.57% at $420.55 at the last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/25/04/44981281/french-drugmaker-sanofi-clocks-20-q1-profit-growth-forecasts-strong-rebound-in-annual-profit" target="_blank" rel="noreferrer noopener">French Drugmaker Sanofi Clocks 20% Q1 Profit Growth, Forecasts Strong Rebound In Annual Profit</a></li>
</ul>
Image: Shutterstock

Movers

Thermo Fisher Doubles Down On US Manufacturing In $2B Expansion Plan

RBC Capital analyst Conor McNamara maintains Thermo Fisher Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>) with a Outperform and lowers the price target from $651 to $637.

RBC Capital Maintains Outperform on Thermo Fisher Scientific, Lowers Price Target to $637

WIIM

Thermo Fisher Scientific shares are trading lower after multiple firms cut their respective price targets on the stock.

UBS analyst Dan Leonard maintains Thermo Fisher Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>) with a Buy and lowers the price target from $715 to $500.

UBS Maintains Buy on Thermo Fisher Scientific, Lowers Price Target to $500

Stifel analyst Daniel Arias maintains Thermo Fisher Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>) with a Buy and lowers the price target from $665 to $620.

Stifel Maintains Buy on Thermo Fisher Scientific, Lowers Price Target to $620

Evercore ISI Group analyst Vijay Kumar maintains Thermo Fisher Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>) with a Outperform and lowers the price target from $585 to $500.

Evercore ISI Group Maintains Outperform on Thermo Fisher Scientific, Lowers Price Target to $500

Wells Fargo analyst Brandon Couillard maintains Thermo Fisher Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>) with a Overweight and lowers the price target from $580 to $570.

Wells Fargo Maintains Overweight on Thermo Fisher Scientific, Lowers Price Target to $570

Baird analyst Catherine Schulte maintains Thermo Fisher Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>) with a Outperform and lowers the price target from $603 to $573.

Baird Maintains Outperform on Thermo Fisher Scientific, Lowers Price Target to $573

Investment demonstrates confidence in America's commitment to science and innovation
Thermo Fisher Scientific Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>), the world leader in serving science, will invest an additional $2 billion in the United States over the next four years, strengthening American innovation, manufacturing and economic competitiveness across the life sciences sector.
As one of the largest manufacturers of medicines in the world, Thermo Fisher enables biopharma companies to develop and produce their medicines in America. These additional investments to the company's American manufacturing capacity support a resilient U.S. healthcare supply chain and will have a strong multiplier effect across the American economy.
The $2 billion investment over the next four years includes:
<ul>
<li>$1.5 billion in capital expenditures to enhance and expand U.S. manufacturing operations</li>
<li>Complemented by $500 million in R&amp;D focused on high-impact innovation</li>
</ul>

Thermo Fisher Scientific To Invest Addl $2B to Enhance U.S. Innovation and Support Customers' Manufacturing

Thermo Fisher Scientific Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>) on Wednesday reported first-quarter 2025 adjusted earnings per share of $5.15, <a href="https://www.benzinga.com/calendars/earnings" target="_blank" rel="noreferrer noopener">beating the street view of $5.10</a>.
Quarterly sales of $10.36 billion, almost flat year over year, outpaced the analyst consensus estimate of $10.23 billion. Organic&nbsp;<a target="_blank" href="https://www.benzinga.com/general/health-care/25/04/44956678/thermo-fisher-scientific-q1-earnings-surpass-estimates-ceo-touts-strong-performance-despite-economic-uncertainty" rel="noreferrer noopener">revenue growth was 1%</a>.
"We delivered very strong performance in the first quarter in a more uncertain macroeconomic environment, and I'm incredibly proud of our team's execution," said Marc Casper, chairman, president, and CEO of Thermo Fisher Scientific. "Our team leveraged the PPI Business System to drive operational excellence and enable our customers' success."
Also Read: <a target="_blank" href="https://www.benzinga.com/25/04/44950727/bristol-myers-cobenfy-falls-short-on-primary-endpoint-in-phase-3-schizophrenia-trial" rel="noreferrer noopener">Bristol Myers&#8217; Cobenfy Falls Short On Primary Endpoint In Phase 3 Schizophrenia Trial, Stock Slides</a>
During its earnings conference call, Thermo Fisher Scientific lowered its fiscal year 2025 adjusted EPS guidance from $23.10-$23.50 to $21.76-$22.84 compared to the consensus of $23.25.
The company revised its 2025 sales guidance from $43.5 billion-$44 billion to $43.3 billion-$44.2 billion compared to consensus of $43.84 billion.
Stephen Williamson, senior vice president &amp; CFO said, &#8220;It&#8217;s worth noting that the tariff-related changes to the guide reduced our adjusted operating income margin by 120 basis points. This is driven by FX and also the tariff costs partially offset by incremental pricing actions. We&#8217;re taking the right actions and protecting the profit dollars, but it has an impact on our reported margins.&#8221;
Williamson said the company expects U.S.-China tariffs to hurt sales in China for products made in the U.S. The company estimates this will reduce revenue by $400 million in 2025. These tariffs will also raise the cost of parts and subassemblies sourced from China. After accounting for lower sales and higher costs—despite efforts to reduce the impact—the company expects adjusted operating income to take a $375 million hit compared to previous guidance.
The company expects slower purchasing in 2025, particularly for instruments and equipment, as it assesses possible changes in government funding and explores new ways to secure funding for ongoing work. It's also planning for a decrease in clinical trial activity, including vaccine-related studies.
Williamson said that looking beyond 2025, the financial impact of broader economic changes should ease fairly quickly thanks to the company&#8217;s strong steps. The company will soon see the full benefits of its supply chain improvements and believes academic customers will adjust how they fund their work and take advantage of new opportunities.
Price Action: TMO stock was up 0.7% at $431.64 on Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/25/04/44955805/avery-dennisons-q1-earnings-come-up-short-with-cautious-outlook-for-q2" target="_blank" rel="noreferrer noopener">Avery Dennison&#8217;s Q1 Earnings Come Up Short, With Cautious Outlook For Q2</a></li>
</ul>
Photo: Shutterstock

Earnings

Guidance

Thermo Fisher Beats Q1 Estimates, Lowers Full-Year Forecast As Tariffs And Costs Take A Toll

Risk-on sentiment dominated Wall Street on Wednesday, as upbeat earnings reports and conciliatory messages from the Trump administration h<a href="https://www.benzinga.com/markets">elped lift investor confidence.</a>
The administration eased market fears on two major fronts that have recently weighed heavily on sentiment. On the trade front, tensions with China appeared to thaw, with reports suggesting the White House is considering reducing tariffs on certain categories of goods.
U.S. Treasury Secretary Scott Bessent added fuel to the rally, stating U.S.-China tariffs are unsustainable and will likely need to be lowered to facilitate meaningful negotiations.
Meanwhile, President Donald Trump offered an abrupt shift in tone toward Federal Reserve Chair Jerome Powell, saying he has no intention to fire him, a remark that helped calm concerns over political interference in monetary policy.
By midday in New York, the S&amp;P 500 was up by nearly 2%, though it had earlier climbed even higher. The Nasdaq 100 outperformed with a 2.5% gain, driven by strength in Magnificent Seven stocks.
Trump's pivot on Powell pushed Treasury yields lower across the curve, with the 30-year yield falling five basis points to 4.83%, after briefly topping 4.90% the previous day.
On the macro front, flash Purchasing Managers&#8217; Index surveys revealed slowing growth momentum in the U.S. economy, as the services sector decelerated sharply following the impact <a href="https://www.benzinga.com/government/regulations/25/04/44952395/us-business-activity-growth-slows-in-april-as-services-suffer-tariff-shock-markets-rally-as-trade-war-cools">of recent tariff shocks.</a>
The U.S. dollar strengthened, while gold plunged 2.6%, heading for its worst session since November.
Oil prices dropped more than 2% following speculation that OPEC+ may announce a new output hike as early as next month.
Meanwhile, Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) held steady around $93,000.
<h1 class="wp-block-heading">Wednesday&#8217;s Performance In Major U.S. Indices, ETFs</h1>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Major Indices</td>
<td>Price</td>
<td>Chg</td>
<td>1-day %</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>18,732.09</td>
<td>+455.68</td>
<td>2.5%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>1,926.45</td>
<td>+37.40</td>
<td>2.0%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>5,384.67</td>
<td>+96.91</td>
<td>1.8%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>39,724.87</td>
<td>+537.89</td>
<td>1.4%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Updated at 12:35 p.m. ET</figcaption></figure>
According to&nbsp;<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent&amp;t=be2bearmibe3na1">Benzinga Pro</a>&nbsp;data:
<ul>
<li>The&nbsp;SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) rose 1.9% to $537.35.</li>
<li>The&nbsp;SPDR Dow Jones Industrial Average&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>) rose 1.4% to $397.79.</li>
<li>The tech-heavy&nbsp;Invesco QQQ Trust Series&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>)&nbsp;rallied 2.7% to $456.50.</li>
<li>The&nbsp;iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) soared 2.1% to $191.47.</li>
<li>The&nbsp;Technology&nbsp;Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLK#NYSE">XLK</a>) outperformed, up 3.44%; the&nbsp;Consumer Staples&nbsp;Select Sector SPDR Fund&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLP#NYSE">XLP</a>) lagged, down 1.2%.</li>
</ul>
<h1 class="wp-block-heading">Wednesday&#8217;s Stock Movers</h1>
<ul>
<li>Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) jumped 6.6% despite falling short on both earnings and revenue expectations, as CEO Elon Musk reassured investors by pledging to scale back his involvement with DOGE and refocus on the company.</li>
</ul>
Other stocks reacting to earnings report included: 
<ul>
<li>Intuitive Surgical Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISRG#NASDAQ">ISRG</a>): up 2.8%</li>
<li>Chubb Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CB#NYSE">CB</a>): down 2.6%</li>
<li>Capital One Financial Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COF#NYSE">COF</a>): up 4.6%</li>
<li>Steel Dynamics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STLD#NASDAQ">STLD</a>): up 4.7%</li>
<li>EQT Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EQT#NYSE">EQT</a>): up 3%</li>
<li>Packaging Corporation of America (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PKG#NYSE">PKG</a>): down 1.7%</li>
<li>Baker Hughes Co. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BKR#NASDAQ">BKR</a>): down 4.3%</li>
<li>Enphase Energy Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENPH#NASDAQ">ENPH</a>): down 14.4%​</li>
<li>Thermo Fisher Scientific Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>): down 0.5%</li>
<li>Philip Morris International Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PM#NYSE">PM</a>): up 2.6%</li>
<li>NextEra Energy, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NEE#NYSE">NEE</a>): up 1%</li>
<li>Boston Scientific Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>): up 4.8%</li>
<li>General Dynamics Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GD#NYSE">GD</a>): down 3.4%</li>
<li>Boeing Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>): up 5.7%</li>
<li>Norfolk Southern Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NSC#NYSE">NSC</a>): up 1.4%</li>
<li>CME Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CME#NASDAQ">CME</a>): down 3.8%</li>
<li>TE Connectivity Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEL#NYSE">TEL</a>): up 2.7%</li>
<li>Amphenol Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APH#NYSE">APH</a>): up 9.9%</li>
<li>AT&amp;T Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/T#NYSE">T</a>): up 0.8%</li>
<li>Old Dominion Freight Line, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ODFL#NASDAQ">ODFL</a>): up 1.3%</li>
<li>Westinghouse Air Brake Technologies Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WAB#NYSE">WAB</a>): up 7.2%</li>
<li>Masco Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MAS#NYSE">MAS</a>): down 2.1%</li>
<li>Avery Dennison Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AVY#NYSE">AVY</a>): down 2.4%</li>
<li>Lennox International Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LII#NYSE">LII</a>): down 8.2%</li>
<li>GE Vernova Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GEV#NYSE">GEV</a>): up 5.2%</li>
<li>Teledyne Technologies Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDY#NYSE">TDY</a>): down 1.7%</li>
<li>Otis Worldwide Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OTIS#NYSE">OTIS</a>): down 6%​</li>
</ul>
<ul>
<li>Stocks slated to report earnings after the bell include Chipotle Mexican Grill, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMG#NYSE">CMG</a>), O'Reilly Automotive, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ORLY#NASDAQ">ORLY</a>), Raymond James Financial, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RJF#NYSE">RJF</a>), Molina Healthcare, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>), Texas Instruments Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TXN#NASDAQ">TXN</a>), FirstEnergy Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FE#NYSE">FE</a>), ServiceNow, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOW#NYSE">NOW</a>), Lam Research Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LRCX#NASDAQ">LRCX</a>), Resmed Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RMD#NYSE">RMD</a>), Discover Financial Services (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DFS#NYSE">DFS</a>), International Business Machines Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IBM#NYSE">IBM</a>), Newmont Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NEM#NYSE">NEM</a>), Rollins Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ROL#NYSE">ROL</a>), United Rentals Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/URI#NYSE">URI</a>), Tyler Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TYL#NYSE">TYL</a>), Edwards Lifesciences Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EW#NYSE">EW</a>), Las Vegas Sands Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LVS#NYSE">LVS</a>), and Alaska Air Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALK#NYSE">ALK</a>).</li>
</ul>
Read Now: 
<ul>
<li><a href="https://www.benzinga.com/economics/macro-economic-events/25/04/44948932/goldman-sachs-backs-copper-tariff-trade-if-trump-slaps-25-duty-on-us-imports">Goldman Sachs Backs &#8216;Copper Tariff Trade&#8217; If Trump Slaps 25% Duty On US Imports</a></li>
</ul>
Photo: Shutterstock

Macro Economic Events

Broad U.S. Equity ETFs

Economics

Federal Reserve

Tech

ETFs

$BTC

SPDR Dow Jones Industrial Average ETF Trust

ENPH

ISRG

LRCX

ODFL

ORLY

OTIS

STLD

TSLA

Select Sector SPDR-Consumer Discretionary

Stocks Surge On China Tariff Hopes, Tesla Jumps, Gold Loses Shine: What's Driving Markets Wednesday?

Thermo Fisher Scientific Inc.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>) reported first-quarter 2025 adjusted earnings per share of $5.15 on Wednesday, <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">beating the street view of $5.10</a>.
Quarterly sales of $10.36 billion, almost flat year over year, outpaced the analyst consensus estimate of $10.23 billion. Organic <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/b44943905/thermo-fisher-scientific-reports-first-quarter-2025-results" rel="noreferrer noopener">revenue growth was 1%</a>.
&#8220;We delivered very strong performance in the first quarter in a more uncertain macroeconomic environment, and I&#8217;m incredibly proud of our team&#8217;s execution,&#8221; said Marc Casper, chairman, president, and CEO of Thermo Fisher Scientific. &#8220;Our team leveraged the PPI Business System to drive operational excellence and enable our customers&#8217; success.&#8221;
Casper added: &#8220;Thermo Fisher is incredibly well-positioned. Our experienced management team has a proven track record, and as the trusted partner to our customers, we will help them manage the current environment, identifying new opportunities and ultimately creating value for all our stakeholders.&#8221;
Also Read: <a target="_blank" href="https://www.benzinga.com/general/health-care/25/03/44440380/3m-spin-off-solventum-targets-higher-margins-eps-growth-in-2025-2028-strategy" rel="noreferrer noopener">3M Spin-Off Solventum Targets Higher Margins, EPS Growth In 2025-2028 Strategy</a>
Thermo Fisher&#8217;s adjusted operating income for the first quarter of 2025 was $2.27 billion, compared with $2.28 billion in the year-ago quarter.
<ul>
<li>Adjusted operating margin was 21.9%, compared with 22% in the first quarter of 2024.</li>
</ul>
Revenue from the Life Sciences Solutions Segment increased by 2.5% year over year to&nbsp;$2.34 billion. Analytical Instruments Segment sales were up 1.8% to $1.72 billion.&nbsp;
Specialty Diagnostics Segment revenues increased 3.5% to $1.15 billion, and Laboratory Products and Biopharma Services segment sales were down 1.5% at $5.64 billion.
Thermo Fisher Scientific agreed to acquire Solventum&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SOLV#NYSE">SOLV</a>) Purification &amp; Filtration business in February for <a target="_blank" href="https://www.benzinga.com/25/02/43940332/thermo-fisher-bets-big-on-bioproduction-with-solventums-unit-deal-worth-41-billion" rel="noreferrer noopener">approximately $4.1 billion in cash</a>.
Solventum's Purification &amp; Filtration business provides purification and filtration technologies for the production of biologics, medical technologies, and industrial applications.
Price Action: Thermo Fisher stock is trading 4.23% higher at $453.10 at the last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/upgrades/25/04/44935871/self-storage-reits-score-upgrade-from-bofa-analyst-8-decline-in-new-construction-helps-sector" target="_blank" rel="noreferrer noopener">Self-Storage REITs Score Upgrade From BofA Analyst: 8% Decline In New Construction Helps Sector</a></li>
</ul>
Image: Shutterstock

SOLV

Thermo Fisher Scientific Q1 Earnings Surpass Estimates, CEO Touts 'Strong Performance' Despite Economic Uncertainty

Thermo Fisher Scientific shares are trading higher after the company reported better-than-expected Q1 financial results.

Press Releases

Thermo Fisher Scientific Increases Quarterly Dividend

Thermo Fisher Scientific to Present at TD Cowen 45th Annual Health Care Conference on March 3, 2025

Thermo Fisher Scientific to Acquire Solventum's Purification and Filtration Business

Solventum Announces Sale of its Purification & Filtration Business to Thermo Fisher Scientific Inc. for $4.1B

Trian Comments on Solventum's Sale of its Purification & Filtration Business

Thermo Fisher Scientific Introduces the Vulcan™ Automated Lab to Transform Semiconductor Analysis

Thermo Fisher Scientific to Hold Earnings Conference Call on Wednesday, April 23, 2025

Thermo Fisher Scientific Reports First Quarter 2025 Results

Thermo Fisher Scientific Invests to Enhance U.S. Innovation and Support Customers' Manufacturing

Thermo Fisher Scientific to Present at BofA Securities 2025 Health Care Conference on May 13

Agilent Technologies

Adaptive Biotechnologies Corporation - Common Stock

Adaptive Biotechnologies

Avantor

Azenta

Bio-Rad Laboratories, Inc. Class A Common Stock

Bio-Rad Laboratories

BioLife Solutions

Bruker

Charles River Laboratories International, Inc. Common Stock

Charles River

Danaher

Evotec SE - American Depositary Shares each representing 1/2 of one ordinary share

Evotec

Illumina

IQVIA Hldgs

Medpace Hldgs

Mesa Laboratories

Mettler-Toledo International, Inc. Common Stock

Mettler-Toledo Intl

Niagen Bioscience

Repligen

Revvity

Sotera Health

Stevanato Group

Bio-Techne

Tempus AI

10x Genomics

Waters

West Pharmaceutical Services, Inc. Common Stock

West Pharmaceutical Servs

Argus Research

Scotiabank

RBC Capital

Stifel

Screenshot 2025-04-15 at 7.03.21 PM

MYNZ

Mainz Biomed Narrows Its Losses, Grows Revenue For Full Year 2024

Screenshot 2024-12-19 at 7.13.05 PM

Quest Diagnostics (NYSE: DGX) And Mainz Biomed (NASDAQ: MYNZ) Team Up To Commercialize ColoAlert Early Cancer Detection Screening In The U.S.

Screenshot 2024-11-21 at 6.41.48 PM

Mainz Biomed Inks Major Deal To Develop A Next-Generation Cancer Test

Screenshot 2024-11-12 at 8.43.58 PM

Healthcare Giant Thermo Fisher Scientific Inc. (NYSE: TMO) Inks Deal With Mainz Biomed (NASDAQ: MYNZ) To Develop And Commercialize Next Gen Colorectal Cancer Screening

Comments

Thermo Fisher Scientific

空売り

Thermo Fisher Scientific (NYSE:TMO) 株価情報, 空売り情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル